220 related articles for article (PubMed ID: 23544172)
1. Notch pathway is activated by MAPK signaling and influences papillary thyroid cancer proliferation.
Yamashita AS; Geraldo MV; Fuziwara CS; Kulcsar MA; Friguglietti CU; da Costa RB; Baia GS; Kimura ET
Transl Oncol; 2013 Apr; 6(2):197-205. PubMed ID: 23544172
[TBL] [Abstract][Full Text] [Related]
2. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
4. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells.
Fiore AP; Fuziwara CS; Kimura ET
Thyroid; 2009 Nov; 19(11):1249-56. PubMed ID: 19725779
[TBL] [Abstract][Full Text] [Related]
5. [The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].
Wang P; Wang YG; Zhao WJ; Fu YD; Wang L; Wang F; Zhao SH
Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):987-91. PubMed ID: 23327964
[TBL] [Abstract][Full Text] [Related]
6. Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer.
Ricarte-Filho JC; Fuziwara CS; Yamashita AS; Rezende E; da-Silva MJ; Kimura ET
Transl Oncol; 2009 Dec; 2(4):236-41. PubMed ID: 19956384
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
8. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.
Knauf JA; Kuroda H; Basu S; Fagin JA
Oncogene; 2003 Jul; 22(28):4406-12. PubMed ID: 12853977
[TBL] [Abstract][Full Text] [Related]
9. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic alterations in papillary thyroid cancers of young patients.
Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
[TBL] [Abstract][Full Text] [Related]
11. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP-mediated growth suppression and MAPK phosphorylation in thyroid papillary carcinoma cells.
Matsumoto H; Sakamoto A; Fujiwara M; Yano Y; Shishido-Hara Y; Fujioka Y; Kamma H
Mol Med Rep; 2008; 1(2):245-9. PubMed ID: 21479404
[TBL] [Abstract][Full Text] [Related]
13. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
14. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
15. Functional Toll-like Receptor 4 Overexpression in Papillary Thyroid Cancer by MAPK/ERK-Induced ETS1 Transcriptional Activity.
Peyret V; Nazar M; Martín M; Quintar AA; Fernandez EA; Geysels RC; Fuziwara CS; Montesinos MM; Maldonado CA; Santisteban P; Kimura ET; Pellizas CG; Nicola JP; Masini-Repiso AM
Mol Cancer Res; 2018 May; 16(5):833-845. PubMed ID: 29523762
[TBL] [Abstract][Full Text] [Related]
16. High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFβ in thyroid follicular cells.
Fuziwara CS; Kimura ET
Thyroid; 2014 Mar; 24(3):453-62. PubMed ID: 23998804
[TBL] [Abstract][Full Text] [Related]
17. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
18. The Highly Expressed FAM83F Protein in Papillary Thyroid Cancer Exerts a Pro-Oncogenic Role in Thyroid Follicular Cells.
Fuziwara CS; Saito KC; Leoni SG; Waitzberg ÂFL; Kimura ET
Front Endocrinol (Lausanne); 2019; 10():134. PubMed ID: 30881348
[TBL] [Abstract][Full Text] [Related]
19. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
